Vistagen Plans Revised Phase 3 Fasedienol Study for Social Anxiety Disorder After FDA Feedback

• Vistagen plans to revise a future Phase 3 trial of fasedienol for social anxiety disorder following FDA feedback.
• Development will target the general patient population for overall treatment, rather than acute treatment alone.
• The planned trial will assess whether acute effects translate into longer-term functional improvement, using the Liebowitz Social Anxiety Scale as its primary endpoint.
• The FDA recognized fasedienol’s reported safety profile and potential to benefit a broad patient population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090830PRIMZONEFULLFEED9873009) on November 09, 2026, and is solely responsible for the information contained therein.